




Association between Vitamin D	levels and	breast cancer risk





• Epidemiologic studies have investigated whether people with higher vitamin D
intakes or higher blood levels of vitamin D have lower risks of specific cancers.
• The results of these studies have been inconsistent, possibly because of the
challenges in carrying out such studies.
• Several randomized trials of vitamin D intake have been carried out, but these
were designed to assess bone health or other non-cancer outcomes.
• Although some of these trials have yielded information on cancer incidence
and mortality, the results need to be confirmed by additional research
because the trials were not designed to study cancer specifically.
https://www.cancer.gov/about-cancer/causes-prevention/risk/diet/vitamin-d-fact-sheet
• Several studies have been done to evaluate the association of vitamin D
deficiency and breast cancer risk. There is controversy in the literature about
this association.
• Current evidence regarding vitamin D and breast cancer was reviewed to inform
clinical practice and identify potential research directions.
• The evidence was inconsistent, inconclusive as to causality, and insufficient to inform
nutritional requirements.
• Current evidence is sufficient to support further study of factors influencing 25(OH)D
levels, associations between 25(OH)D levels and breast cancer in premenopausal and
Black women, moderate dose (≤2,000 IU D3/day) supplemental vitamin D use and
breast cancer incidence, and observational studies evaluating whether a threshold
higher 25(OH)D level is associated with adverse clinical outcome in women with
breast cancer.
• Before routine clinical application of any strategies targeting vitamin D status for
breast cancer prevention or therapy are undertaken, the limitations of the current






• Confounding, reverse causation and various biases can generate the associations,
and even with careful study design and statistical adjustment, incorrect causal
inference is possible
• The recognition of these problematic aspects of epidemiological investigation has
led to the application of a series of methods aimed at improving causal
inference
• A successful approach is to use genetic variants as exposure indicators that are
not subject to the influences that vitiate conventional study designs, an
approach known asMendelian randomization (MR)
Mendelian Randomization:	Genes	as	Instrumental	Variables
• Mendelian randomization (MR) is a method of using measured variation in genes of
known function to examine the causal effect of a modifiable exposure on disease in
non-experimental studies.
• Mendelian randomization is a method that allows one to test for, or in certain cases
to estimate, a causal effect from observational data in the presence of confounding
factors.
• From a statistical point of view, MR is an application of the technique of instrumental
variables with genotype acting as an instrument for the exposure of interest.
• Because genotypes are assigned randomly when passed from parents to offspring
during meiosis, if we assume that choice of mate is not associated with genotype
(panmixia), then the population genotype distribution should be unrelated to the
confounders that typically plague observational epidemiology studies.
• In this regard, Mendelian randomization can be thought of as a “natural”
randomized controlled trial.
• Because the polymorphism is the instrument, Mendelian randomization is
dependent on genetic association studies having provided good candidate genes
for response to risk exposure.
• The design of MR was first proposed in 1986:
Katan MB. Apolipoprotein E isoforms, serum cholesterol, and cancer. Lancet. 1986
Mar 1;1(8479):507-8.
• Gray and Wheatley (1991) describe it as a method for obtaining unbiased
estimates of the effects of a putative causal variable without conducting a
traditional randomized trial. These authors also coined the term Mendelian
randomization.
Gray R, Wheatley K. How to avoid bias when comparing bone marrow transplantation
with chemotherapy. Bone Marrow Transplant. 1991;7 Suppl 3:9-12. Review
• Associations between modifiable exposures and disease seen in observational
epidemiology are sometimes confounded and thus misleading, despite our best efforts
to improve the design and analysis of studies.
• Frequent use of causal vocabulary to express something that is more than
association between genotypes, intermediate phenotypes and disease.
• While this is common practice in the medical literature where underlying
knowledge about the biology of the problem may indeed allow one to deduce
the direction of an observed association and where ‘causal pathways’ for
disease are familiar concepts, it is important for our purposes that we make





Objective: To assess the association between Vitamin D levels (blood 25-hydroxyvitamin D
levels (25(OH)D) and breast cancer risk using a Mendelian randomization approach.
Design:MCC-Study (Case-Control, “Breast Cancer”)
1. SNPs related with Vitamin D levels (SNPs VD)
2. Association Vitamin D levels and SNPs VD (vs Polygenic Risk Score) (Additive model)
(N=432) (linear regression models)
3. Association SNPs VD and Breast Cancer risk (vs Polygenic Risk Score) (Additive model)
(Cases=1019,Controls=1195) (mixed logistic regression models)
4. MR causal estimates and MR assumptions
Genotyping:MCC-Exome Array




(1) The instrumental variable assumptions:
i. the genetic variant is associated with the risk factor.
ii. the genetic variant is not associated with confounders of the risk factor–outcome
relationship.
iii. the genetic variant is not associated with the outcome conditional on the risk factor and
confounders of the risk factor–outcome relationship.
(2) In addition to direct effects of the instrument on the disease misleading the analyst:
- Misleading conclusions may also arise in the presence of linkage disequilibrium with
unmeasured directly-causal variants, genetic heterogeneity, pleiotropy (often detected as a





























































































(kcal*kg-1*h-1) 13.8	± 22.3 14.0	± 22.3







































































































Results from Various Mendelian Randomization Methods for Adjusted Models
Method Estimate Std Error 95% CI P-value
Simple median -0.011 0.014 -0.038 0.016 0.421
Weighted median -0.022 0.008 -0.038 -0.006 0.007
Penalized weighed median -0.022 0.008 -0.038 -0.006 0.007
IVW -0.017 0.006 -0.029 -0.006 0.004
Penalized IVW -0.017 0.006 -0.029 -0.006 0.004
Robust IVW -0.019 0.008 -0.034 -0.004 0.004
Penalized robust IVW -0.019 0.008 -0.034 -0.004 0.004
MR-Egger -0.026 0.009 -0.044 -0.007 0.006
(intercept) 0.039 0.027 -0.014 0.093 0.148
Penalized MR-Egger -0.026 0.009 -0.044 -0.007 0.006
(intercept) 0.039 0.027 -0.014 0.093 0.148
Robust MR-Egger -0.026 0.005 -0.036 -0.016 0.000
(intercept) 0.036 0.022 -0.007 0.079 0.102
Penalized robust MR-Egger -0.026 0.005 -0.036 -0.016 0.000
(intercept) 0.036 0.022 -0.007 0.079 0.102













“A consortium of leading European research centres and pharmaceutical companies will this
week announce a plan to transform epidemiology by combining it with the new techniques of
high-throughput biology”.

